Female sex hormones and symptoms of obstructive sleep apnea in European women of a population-based cohort.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
11
2021
accepted:
23
05
2022
entrez:
22
6
2022
pubmed:
23
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
The prevalence of obstructive sleep apnea is higher in women after menopause. This is suggested to be a result of an altered sex hormone balance but has so far not been confirmed in a population-based study. To investigate whether serum concentration of estrogens and progesterone are associated with the prevalence of sleep apnea symptoms in middle-aged women of the general population. We analyzed data from 774 women (40-67 years) from 15 study centers in seven countries participating in the second follow-up of the European Community Respiratory Health Survey (2010-2012). Multiple logistic regression models were fitted with self-reported symptoms of sleep apnea as outcomes and serum concentrations of various estrogens and progesterone as predictors. All analyses were adjusted for relevant covariates including age, BMI, education, study center, smoking habits, and reproductive age. Among all included women, a doubling of serum concentrations of estrone and progesterone was associated with 19% respectively 9% decreased odds of snoring. Among snorers, a doubling of the concentrations of 17β-estradiol, estrone and estrone 3-sulfate was associated with 18%, 23% and 17% decreased odds of breathing irregularly, and a doubling of the progesterone concentration was further associated with 12% decreased odds of waking up suddenly with a chocking sensation. Other evaluated associations were not statistically significant. Middle-aged women with low serum estrogen and progesterone levels are more likely to snore and report symptoms of obstructive sleep apnea.
Sections du résumé
BACKGROUND
The prevalence of obstructive sleep apnea is higher in women after menopause. This is suggested to be a result of an altered sex hormone balance but has so far not been confirmed in a population-based study.
OBJECTIVE
To investigate whether serum concentration of estrogens and progesterone are associated with the prevalence of sleep apnea symptoms in middle-aged women of the general population.
METHODS
We analyzed data from 774 women (40-67 years) from 15 study centers in seven countries participating in the second follow-up of the European Community Respiratory Health Survey (2010-2012). Multiple logistic regression models were fitted with self-reported symptoms of sleep apnea as outcomes and serum concentrations of various estrogens and progesterone as predictors. All analyses were adjusted for relevant covariates including age, BMI, education, study center, smoking habits, and reproductive age.
RESULTS
Among all included women, a doubling of serum concentrations of estrone and progesterone was associated with 19% respectively 9% decreased odds of snoring. Among snorers, a doubling of the concentrations of 17β-estradiol, estrone and estrone 3-sulfate was associated with 18%, 23% and 17% decreased odds of breathing irregularly, and a doubling of the progesterone concentration was further associated with 12% decreased odds of waking up suddenly with a chocking sensation. Other evaluated associations were not statistically significant.
CONCLUSIONS
Middle-aged women with low serum estrogen and progesterone levels are more likely to snore and report symptoms of obstructive sleep apnea.
Identifiants
pubmed: 35731786
doi: 10.1371/journal.pone.0269569
pii: PONE-D-21-34924
pmc: PMC9216532
doi:
Substances chimiques
Estrogens
0
Gonadal Steroid Hormones
0
Estrone
2DI9HA706A
Progesterone
4G7DS2Q64Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0269569Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Sleep. 2017 Aug 1;40(8):
pubmed: 28633495
Trends Cardiovasc Med. 2017 May;27(4):280-289
pubmed: 28143688
Continuum (Minneap Minn). 2017 Aug;23(4, Sleep Neurology):1093-1116
pubmed: 28777178
J Thorac Dis. 2015 Aug;7(8):1311-22
pubmed: 26380759
Am J Respir Crit Care Med. 2001 Mar;163(3 Pt 1):608-13
pubmed: 11254512
Biomed Pharmacother. 2018 Jun;102:403-411
pubmed: 29573619
J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
pubmed: 11768292
Am J Respir Crit Care Med. 2002 May 1;165(9):1217-39
pubmed: 11991871
Am J Epidemiol. 2013 May 1;177(9):1006-14
pubmed: 23589584
Sleep Med Rev. 2012 Dec;16(6):529-37
pubmed: 22425225
Respir Physiol Neurobiol. 2017 May;239:46-54
pubmed: 28189710
Maturitas. 2015 Feb;80(2):170-8
pubmed: 25481384
Endocr Connect. 2017 Oct;6(7):437-445
pubmed: 28739562
Ann Epidemiol. 2015 Oct;25(10):779-84.e1
pubmed: 26358364
Sleep Breath. 2020 Mar;24(1):7-13
pubmed: 31309463
Menopause. 2017 Jan;24(1):112-117
pubmed: 27648659
Nat Sci Sleep. 2016 Jun 29;8:197-205
pubmed: 27418861
PLoS One. 2020 Jun 30;15(6):e0235478
pubmed: 32603379
J Womens Health (Larchmt). 2017 Mar;26(3):259-265
pubmed: 28103130
J Am Coll Cardiol. 2017 Feb 21;69(7):841-858
pubmed: 28209226
Sleep Breath. 2003 Mar;7(1):25-9
pubmed: 12712394
Biomed Res Int. 2014;2014:757461
pubmed: 24734243
Menopause. 1999 Fall;6(3):196-200
pubmed: 10486788
Respir Med. 2004 Oct;98(10):984-9
pubmed: 15481275
Eur J Clin Invest. 2003 Dec;33(12):1084-9
pubmed: 14636291
Sci Rep. 2016 Jun 02;6:27088
pubmed: 27250523
J Hum Hypertens. 2015 Dec;29(12):705-12
pubmed: 25761667
Sleep Med Rev. 2020 Feb;49:101225
pubmed: 31739179
Chest. 2014 Nov;146(5):1387-1394
pubmed: 25367475
Sleep Breath. 2018 Mar;22(1):241-249
pubmed: 28197893